Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1931 1
1976 1
1987 1
1988 1
1991 1
1992 3
1993 3
1994 2
1995 3
1996 9
1997 6
1998 2
1999 3
2000 4
2001 3
2002 3
2003 3
2004 7
2005 6
2006 3
2007 7
2008 2
2009 2
2010 7
2011 4
2012 3
2013 1
2014 1
2015 4
2016 1
2017 4
2018 3
2019 1
2020 1
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 10674051

105 results
Results by year
Filters applied: . Clear all
Page 1
To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.
Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. Clark WF, et al. CMAJ. 2000 Jan 25;162(2):195-8. CMAJ. 2000. PMID: 10674051 Free PMC article.
Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism.
Vegter S, Perna A, Hiddema W, Ruggenenti P, Remuzzi G, Navis G, Postma MJ. Vegter S, et al. Pharmacogenet Genomics. 2009 Sep;19(9):695-703. doi: 10.1097/FPC.0b013e3283307ca0. Pharmacogenet Genomics. 2009. PMID: 19696696
Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor.
Costa-Scharplatz M, van Asselt AD, Bachmann LM, Kessels AG, Severens JL. Costa-Scharplatz M, et al. Pharmacogenet Genomics. 2007 May;17(5):359-68. doi: 10.1097/01.fpc.0000236336.34175.e8. Pharmacogenet Genomics. 2007. PMID: 17429318
Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?
Kiberd BA, Jindal KK. Kiberd BA, et al. Mayo Clin Proc. 1999 Jun;74(6):559-64. doi: 10.4065/74.6.559. Mayo Clin Proc. 1999. PMID: 10377929
Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany.
Adarkwah CC, Gandjour A. Adarkwah CC, et al. Int J Technol Assess Health Care. 2010 Jan;26(1):62-70. doi: 10.1017/S0266462309990584. Int J Technol Assess Health Care. 2010. PMID: 20059782
The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
Golan L, Birkmeyer JD, Welch HG. Golan L, et al. Ann Intern Med. 1999 Nov 2;131(9):660-7. doi: 10.7326/0003-4819-131-9-199911020-00005. Ann Intern Med. 1999. PMID: 10577328 Free article.
Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model.
Campbell HM, Boardman KD, Dodd MA, Raisch DW. Campbell HM, et al. Ann Pharmacother. 2007 Jul;41(7):1101-10. doi: 10.1345/aph.1K074. Epub 2007 Jul 3. Ann Pharmacother. 2007. PMID: 17609233
Patient compliance with drug therapy for diabetic nephropathy.
Hughes D, Manns B. Hughes D, et al. CMAJ. 2000 May 30;162(11):1553-4. CMAJ. 2000. PMID: 10862223 Free PMC article. No abstract available.
Renal effects of angiotensin-converting enzyme inhibitors that result in cost savings and improved patient outcomes.
Swislocki AL, Siegel D. Swislocki AL, et al. Am J Manag Care. 2001 Mar;7(3):283-95. Am J Manag Care. 2001. PMID: 11258145 Free article. Review.
To treat or not to treat? Cost-effectiveness of ace inhibitors in non-diabetic advanced renal disease - a Dutch perspective.
Adarkwah CC, Gandjour A, Akkerman M, Evers S. Adarkwah CC, et al. Kidney Blood Press Res. 2013;37(2-3):168-80. doi: 10.1159/000350142. Epub 2013 May 6. Kidney Blood Press Res. 2013. PMID: 23689440 Free article.
105 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback